復宏漢霖(02696)HLX37 1期臨床研究完成首例患者給藥 X
29/12/2025 17:49
<匯港通訊>    復宏漢霖(02696)宣佈,近日,公司自主研發的HLX37(重組人源化抗PD-L1與抗VEGF雙特異性抗體注射液)(HLX37)在晚期/轉移性實體瘤患者中的1期臨床研究於中國境內(不包括港澳台地區)完成首例患者給藥。 (WL)



Infocast Limited and its information providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.